recro pharma inc (RAH) Key Developments
Recro Pharma, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 14 15
Recro Pharma, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $18,660,000. Operating income was $373,000 compared with operating loss of $2,796,000 for the same period a year ago. Net loss applicable to common shareholders was $1,311,000 or $0.17 per basic and diluted share compared with $2,794,000 or $0.36 per basic and diluted share for the same period a year ago.
For the six months, the company reported total revenues of $18,660,000. Operating loss was $3,770,000 compared with $3,670,000 for the same period a year ago. Net loss applicable to common shareholders was $5,450,000 or $0.70 per basic and diluted share compared with $9,210,000 or $1.94 per basic and diluted share for the same period a year ago. There were no revenues and costs of sales in the comparable periods in 2014. The increases in revenues and costs of sales were the result of the acquired manufacturing business from Alkermes.
Recro Pharma Appoints Scott Rizzo as General Manager
Jul 20 15
Recro Pharma, Inc. announced the appointment of Scott Rizzo as General Manager of the company's contract manufacturing facility located in Gainesville, Georgia. Scott brings 25 years of experience and a seasoned manufacturing background to Recro Pharma at an important and exciting time for the company. Mr. Rizzo joins Recro Pharma from J. Knipper where he served as General Manager.
Recro Pharma, Inc. Announces Positive Results for Phase II Clinical Trial of Dex-IN
Jul 17 15
Recro Pharma, Inc. announced positive efficacy results in the Phase II clinical trial for Dex-IN, a proprietary intranasal
formulation of dexmedetomidine, for the treatment of acute pain in adult patients undergoing bunionectomy surgery. Dex-IN met the primary endpoint of the clinical trial in demonstrating significant pain relief compared with placebo over 48 hours. The company plans to meet with the FDA to discuss the Company's Phase III plans and determine what, if any, additional information will be required in association with the Phase III clinical program for Dex-IN. The Phase II trial was a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma's proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. Patients who met the eligibility criteria were randomized to either a 50 g dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients remained under observation for 48 hours at study centers. Patients were followed for 7 days after the initial dose of study medication. There was an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. A total of 168 patients were randomized and received study medication in the clinical trial, 84 patients in each treatment group. Seven patients discontinued the study early, six for lack of efficacy (three in each treatment group) and one for a serious adverse event of hypotension. The primary efficacy endpoint of the trial was the summed pain intensity difference over 48 hours, SPID48, starting on Post Op Day 1. Additional efficacy endpoints included use of opioid rescue medication, SPIDs over various time intervals, as well as other standard efficacy analyses. The most common adverse events observed in the study were blood pressure decrease /hypotension, nausea (similar incidences to placebo), nasal discomfort and headache. An adverse event of bradycardia was reported in 3 subjects in the Dex-IN treatment group.
Recro Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:30 AM
May 28 15
Recro Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Geraldine A. Henwood, Chief Executive Officer, President and Director.
Recro Pharma, Inc. Reports Financial Results for the First Quarter Ended March 31, 2015
May 12 15
Recro Pharma, Inc. reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, he c reported a net loss applicable to common shareholders of $4.1 million, or $0.53 per basic and diluted share, compared to a net loss applicable to common shareholders of $6.4 million, or $3.67 per basic and diluted share, for the comparable period in 2014.